Inpatient Hypoglycemia
The most common inpatient endocrine emergency. Every episode of glucose < 70 requires intervention. Recurrent hypoglycemia increases mortality independent of the cause.
🔍 Overview
Overview
Inpatient hypoglycemia (glucose < 70 mg/dL) affects up to 10-30% of hospitalized diabetic patients and is independently associated with increased mortality, longer LOS, and ICU transfer. NICE-SUGAR, NEJM 2009 Classified as: Level 1 (54-70 mg/dL, alert), Level 2 (< 54, clinically significant), Level 3 (severe, requiring assistance from another person). Most common causes: (1) insulin-food mismatch (holding meals while continuing insulin), (2) renal insufficiency (reduced insulin clearance), (3) reduced PO intake (NPO, nausea, surgery), (4) medication errors. Key principle: every hypoglycemic event is preventable and deserves root cause analysis. The attending will ask "why did this happen and what did you change?"
🧪 Workup
Workup
- Confirm with venous glucose -point-of-care glucometers are less accurate at low ranges. Whipple's triad: symptoms + low glucose + symptom resolution with glucose correction.
- Review insulin/secretagogue doses -#1 cause. Check timing of last insulin dose vs last meal. Basal insulin too high? Sliding scale overlapping with scheduled dose?
- BMP -Cr (AKI/CKD reduces insulin clearance → prolonged insulin effect), hepatic function (reduced gluconeogenesis)
- Medication reconciliation -sulfonylureas (long-acting, especially in CKD), insulin dose errors, fluoroquinolones (rare), pentamidine, beta-blockers (mask symptoms)
- NPO status -was patient made NPO for procedure while basal insulin continued?
- Nutrition assessment -decreased PO intake, skipped meals, vomiting, new tube feed interruption
- If non-diabetic unexplained hypoglycemia: insulin level + C-peptide + proinsulin + sulfonylurea screen (draw DURING hypoglycemia). High insulin + high C-peptide = endogenous hyperinsulinism (insulinoma). High insulin + low C-peptide = exogenous insulin. High C-peptide + positive SU screen = sulfonylurea use.
- Cortisol -if adrenal insufficiency suspected (especially if recurrent hypoglycemia with hypotension)
🚨 Management
Management
- Reduce basal insulin by 20-40% if the episode occurred overnight or fasting ADA Standards of Care, 2026
- Hold or reduce prandial insulin if patient is eating less than usual or NPO
- Discontinue sulfonylurea in CKD/AKI (long half-life → recurrent hypoglycemia for 24-72h)
- Adjust sliding scale -reduce correction factor if consistently hypoglycemic
- Ensure meal delivery before prandial insulin -coordinate with nursing
- Hold prandial insulin if patient is NPO -only continue basal (and reduce by 20-50%)
Sulfonylurea-induced hypoglycemia (especially glipizide/glyburide in CKD) can recur for 24-72 hours even after initial correction. These patients need D10 drip + hourly glucose checks + admission for observation. Octreotide 50 mcg SQ q6h can reduce insulin secretion in refractory cases.
💊 Medications
Medications
| Drug | Dose | Route | Notes |
|---|---|---|---|
| D50W (Dextrose 50%) | 25g (50 mL) IV push | IV | First-line for severe/unable to eat. Repeat q15min PRN. Causes phlebitis -use large bore IV. |
| D10W drip | 50-100 mL/hr | IV | For recurrent hypoglycemia (especially sulfonylurea-induced). Prevents repeated D50 pushes. |
| Glucagon | 1 mg IM/SQ | IM/SQ | If no IV access. Mobilizes hepatic glycogen. Ineffective if glycogen-depleted (alcoholics, liver failure). Causes nausea. |
| Octreotide (Sandostatin) | 50 mcg SQ q6h | SQ | For sulfonylurea-induced hypoglycemia refractory to D10. Suppresses insulin release from pancreatic beta cells. McLaughlin, 2000 |
| Oral glucose (juice/tabs) | 15-20g fast-acting carbs | PO | First-line if alert + able to swallow. Follow with complex carbs. Recheck at 15 min. |
🏥 Rounds
Pimp Questions
❓ Why is sulfonylurea-induced hypoglycemia more dangerous than insulin-induced?
Sulfonylureas (especially glyburide and glipizide) have long half-lives (12-24h+) that are prolonged further in CKD. Unlike insulin which has a predictable duration, sulfonylureas can cause recurrent hypoglycemia for 24-72 hours even after initial correction. This is why patients need D10 drip + observation, not just a D50 push and discharge. Octreotide can help by suppressing insulin release.
❓ How do you differentiate insulinoma from exogenous insulin administration?
Draw labs during hypoglycemia: Insulinoma: high insulin + high C-peptide + high proinsulin (endogenous production). Exogenous insulin: high insulin + LOW C-peptide (exogenous insulin suppresses endogenous production). Sulfonylurea use: high insulin + high C-peptide + positive sulfonylurea screen. C-peptide is the key differentiator because commercial insulin preparations do not contain C-peptide.
❓ When should you use octreotide for hypoglycemia?
Sulfonylurea-induced hypoglycemia refractory to D10 drip. Octreotide (somatostatin analog) suppresses insulin secretion from pancreatic beta cells. Dose: 50 mcg SQ q6h. It is NOT useful for insulin-induced hypoglycemia (the problem is exogenous insulin, not endogenous secretion). Consider in: recurrent hypoglycemia despite D10, glipizide/glyburide with CKD, intentional sulfonylurea ingestion. McLaughlin, 2000
❓ What insulin adjustments should you make after an inpatient hypoglycemic event?
Root cause analysis + immediate order changes: (1) If overnight/fasting hypo → reduce basal insulin by 20-40%. (2) If post-prandial hypo → reduce prandial/correction dose. (3) If NPO → hold prandial, reduce basal by 20-50%. (4) If on sulfonylurea + AKI/CKD → STOP sulfonylurea. (5) If multiple sliding scale corrections overlapping → simplify regimen. Document the analysis and changes in your note -this is expected by attendings.
❓ Why does glucagon not work in alcoholic or liver failure patients?
Glucagon works by mobilizing hepatic glycogen stores (glycogenolysis). In chronic alcoholics and liver failure patients, glycogen stores are depleted (alcohol inhibits gluconeogenesis + poor nutritional intake). Without glycogen to break down, glucagon is ineffective. These patients need IV dextrose (D50 or D10 drip) -there is no alternative.
❓ What is the "rule of 15" for hypoglycemia?
For alert patients who can eat: give 15 grams of fast-acting carbohydrate (4 oz juice, 3-4 glucose tabs) → recheck glucose in 15 minutes → repeat if still < 70. Once glucose > 70, follow with a complex carbohydrate snack to prevent recurrence. Simple and effective -but only works if the patient can protect their airway and swallow safely.
Sample Presentation
Mr. Garcia is a 68-year-old man with T2DM on glargine 40 units + glipizide 10 mg BID, admitted for pneumonia, found to have fingerstick glucose of 38 at 3 AM. Diaphoretic, confused. Last meal was dinner at 5 PM (ate 50% of tray). Cr 2.4 (baseline 1.2). Received full sliding scale correction of 6 units at 9 PM for glucose of 220.
Key Points: Three contributors: (1) Glipizide in AKI (reduced clearance → prolonged hypoglycemic effect), (2) reduced PO intake, (3) sliding scale correction on top of basal + sulfonylurea. Immediate: D50 25g IV → start D10 drip. Prevent: STOP glipizide (always in AKI). Reduce glargine by 40% (24 units). Reduce sliding scale. This patient needs q1h glucose checks × 24h because glipizide will continue to cause hypoglycemia.
- Fingerstick glucose q15 min until glucose > 100 and stable
- Then q1h × 4h to ensure no recurrence (especially with long-acting insulin or sulfonylureas)
- Resume regular glucose monitoring (AC/HS or q6h) once stable
- Review all insulin orders after ANY hypoglycemic event -this is the intern's most important action
- Notify attending of any Level 2 (< 54) or Level 3 (severe) hypoglycemia
- Hypoglycemia event report -many hospitals require formal incident reporting
- Pre-prandial glucose + post-meal check if adjusting regimen -verify effectiveness of changes
- A1c -helps guide discharge insulin regimen (A1c < 7% on insulin = possibly over-basal'd)
📋 Summary
Summary
Every Value Below 70 Needs Action
Glucose below 70 mg/dL is the intervention threshold; below 54 is clinically significant hypoglycemia. Recurrent hypoglycemia raises mortality independently of whatever caused it, so it is treated as an event to be investigated, not a number to be corrected and forgotten.
Treat by Route the Patient Can Use
Alert and able to swallow → 15 to 20 g of fast-acting carbohydrate, then recheck in 15 min and follow with a complex carbohydrate or the next meal so it does not simply recur. Obtunded or unable to eat → D50W 25 g IV push, repeatable every 15 min. No IV access → glucagon 1 mg IM.
Glucagon Fails in the Patients Who Need It Most
It works by mobilizing hepatic glycogen, so it does nothing when the stores are empty. Expect it to fail in alcohol use disorder, malnutrition, prolonged fasting and advanced liver disease, which are exactly the populations that present with severe hypoglycemia. Get IV access and give dextrose.
Sulfonylureas Recur for Days
Glipizide and especially glyburide, above all in chronic kidney disease, cause hypoglycemia that recurs for 24 to 72 h after the first correction. A single amp of D50 and a normal recheck is a trap: these patients need a D10 infusion, hourly glucose checks and admission for observation, and octreotide 50 mcg SC q6h when they keep dropping despite dextrose, because it suppresses the insulin release the drug keeps driving.
Find the Cause, Not Just the Number
Review every glucose-lowering agent and its timing against meals, then look for the change that precipitated it: a missed or held meal, a new NPO order, acute kidney injury reducing insulin clearance, sepsis, adrenal insufficiency, liver failure, or steroids being tapered off.
The Commonest Inpatient Causes Are Iatrogenic
Insulin given for a meal the patient did not eat, a correction scale stacked on top of scheduled insulin, sudden NPO status, and failure to reduce doses when the kidney fails. These are order-writing problems, so the fix is in the orders: match mealtime insulin to actual intake, and reduce the dose when renal function falls.
Draw the Critical Sample Before You Treat
In an unexplained hypoglycemia with no diabetes, get insulin, C-peptide, proinsulin, beta-hydroxybutyrate and a sulfonylurea screen while the glucose is still low. High insulin with high C-peptide means endogenous, an insulinoma or a sulfonylurea, which the drug screen separates. High insulin with low C-peptide means exogenous insulin. Once the sugar is corrected the sample is uninterpretable.
Prevent the Next One
Document the episode and change something. Reduce or reschedule the offending dose, loosen the glycemic target in the elderly and in advanced kidney disease, move off glyburide, and give bedtime snacks where nocturnal events are the pattern. Also warn about hypoglycemia unawareness: repeated episodes blunt the adrenergic warning symptoms, so the next event presents as confusion or seizure with no preceding shakiness.
📄 One Pager
Text version
One-Pager
Inpatient Hypoglycemia
Treat, prevent, document
Immediate
Alert: 15g PO carbs → recheck 15 min. AMS/NPO: D50 25g IV → repeat PRN → D10 drip. No IV: glucagon 1 mg IM.
Prevent Recurrence
Reduce basal 20-40%. STOP sulfonylurea in AKI. Hold prandial if NPO. Ensure meal before prandial insulin. SU hypo: D10 drip + octreotide + observe 24-72h.
Workup If Non-Diabetic
Draw DURING hypo: insulin, C-peptide, proinsulin, sulfonylurea screen. High insulin + low C-peptide = exogenous. High insulin + high C-peptide = insulinoma or SU.
Related Topics
Adrenal CrisisCushing's SyndromeDiabetes InsipidusHypercalcemiaHyperosmolar Hyperglycemic State (HHS)Hyperthyroidism / Graves' Disease